News

Stay up-to-date with information about Summit Re as well as news and events from around our industry. Bookmark this page and check back often! 

Featured
Cell & Gene Therapy Approval Updates

Read 2025’s final cell and gene therapy updates.

Summit Re and iiSi Realign Operations

Together with its parent, Companion Life Insurance Company, Summit Re has announced plans to realign operations with iiSi, a division of Companion Life Insurance Company. In this move, Summit Re will shift its employer stop loss (ESL) business to iiSi.

FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy
FDA Approves New Safety Warning and Revised Indication that Limits Use for Elevidys Following Reports of Fatal Liver Injury
Dystrophic Epidermolysis Bullosa (DEB): What You Need to Know

Dystrophic epidermolysis bullosa (DEB) is a condition caused by mutations in gene COL7A in which skin becomes fragile and prone to blistering. For people with DEB, any injury or friction on the skin can lead to the formation of painful blisters.

Featured
Summit Re and iiSi Realign Operations
Gene Therapy and Skin Substitute Updates
Brian Fehlhaber Retires from Summit Re
Tonya Crawford Recognized By Captive International
Gene Therapy Update: SRP-9001 delandistrogene moxeparvovec for DMD